Sign in

    Athena Chin

    Biotechnology Equity Research Analyst at TD Cowen

    Athena Chin is a Biotechnology Equity Research Analyst at TD Cowen, specializing in the biotech sector with a particular focus on companies such as Compass Pathways and Spero Therapeutics. She is recognized for providing detailed analyses of clinical trial activities and regulatory developments, often engaging directly with management teams across the sector. Athena began her career after earning a BA from Barnard College, and has served as a Research Associate at TD Securities (USA) LLC before advancing to her current analyst role at TD Cowen. Her professional credentials include in-depth sector coverage and a strong educational foundation, marking her as a rising expert in biotechnology equity research.

    Athena Chin's questions to COMPASS Pathways (CMPS) leadership

    Athena Chin's questions to COMPASS Pathways (CMPS) leadership • Q2 2025

    Question

    Athena Chin from TD Cowen asked if Compass is pursuing the commissioner's national priority voucher and what their understanding is of the eligibility criteria.

    Answer

    CEO Kabir Nath confirmed that Compass has submitted an application for the voucher. He explained that they believe they clearly meet three of the five criteria: significant need, public health crisis, and innovative treatment. He also noted their readiness to submit filing package elements, another requirement for the program.

    Ask Fintool Equity Research AI